Cytokine release syndrome : inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality
Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
European cytokine network - 31(2020), 3 vom: 01. Sept., Seite 81-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moradian, Negar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 31.12.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/ecn.2020.0451 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319253422 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319253422 | ||
| 003 | DE-627 | ||
| 005 | 20231225171049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1684/ecn.2020.0451 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319253422 | ||
| 035 | |a (NLM)33361013 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moradian, Negar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytokine release syndrome |b inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corona virus | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Gouravani, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Salehi, Mohammad Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Heidari, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Shafeghat, Melika |e verfasserin |4 aut | |
| 700 | 1 | |a Hamblin, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European cytokine network |d 1997 |g 31(2020), 3 vom: 01. Sept., Seite 81-93 |w (DE-627)NLM012648205 |x 1952-4005 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2020 |g number:3 |g day:01 |g month:09 |g pages:81-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/ecn.2020.0451 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2020 |e 3 |b 01 |c 09 |h 81-93 | ||